MedTrace Logo

Study of the Pharmacokinetics of Daptomycin in Children With Renal Disease

NCT01012089 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2018-06-06

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to:

1. Study the pharmacokinetics and safety of daptomycin in children on hemodialysis (HD) and peritoneal dialysis (PD).
2. Determine urine, HD and PD clearance of daptomycin.

Conditions

Interventions

DRUG

Daptomycin

Daptomycin IV 5 mg/kg one time dose

Sponsors & Collaborators

  • Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

    collaborator INDUSTRY

  • University of Oklahoma

    lead OTHER

Principal Investigators

  • Teresa V Lewis, Pharm.D. · University of Oklahoma

  • Martin A Turman, M.D., Ph.D. · University of Oklahoma

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2014-04-30
Completion
2014-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01012089 on ClinicalTrials.gov